Skip to main content

Table 2 Dosimetry of 64Cu-NOTA-Trastuzumab (OLINDA)

From: A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer

Organ Absorbed dose (mGv/MBq)
64Cu-NOTA-Trastuzumab 64Cu-DOTA-Trastuzumab [6] [89Zr]Trastuzumab [9]
Adrenals 0.005 ± 0.001 0.031 ± 0.004 0.80
Brain 0.009 ± 0.002 0.015 ± 0.003 0.39
Breasts 0.002 ± 0.000 0.020 ± 0.001 0.42
Gallbladder wall 0.006 ± 0.001 0.035 ± 0.008 0.86
LLI wall 0.000 ± 0.000 0.018 ± 0.002 0.58
Small intestine 0.001 ± 0.000 0.019 ± 0.001 0.57
Stomach wall 0.008 ± 0.002 0.024 ± 0.002 0.63
ULI wall 0.002 ± 0.000 0.022 ± 0.002 0.65
Heart wall 0.042 ± 0.008 0.340 ± 0.046 1.11
Kidneys 0.044 ± 0.009 0.103 ± 0.034 1.23
Liver 0.076 ± 0.007 0.237 ± 0.117 1.63
Lungs 0.034 ± 0.004 0.057 ± 0.070 0.59
Muscle 0.001 ± 0.000 0.023 ± 0.006 0.49
Ovaries 0.001 ± 0.000 0.018 ± 0.002 0.59
Pancreas 0.005 ± 0.001 0.032 ± 0.003 0.78
Red marrow 0.001 ± 0.000 0.017 ± 0.001 0.69
Osteogenic cells 0.001 ± 0.000 0.035 ± 0.001 0.79
Skin 0.001 ± 0.000 0.015 ± 0.001 0.34
Spleen 0.063 ± 0.010 0.142 ± 0.040 0.86
Thymus 0.003 ± 0.000 0.030 ± 0.002 0.57
Thyroid 0.000 ± 0.000 0.016 ± 0.001 0.43
Urinary 0.003 ± 0.001 0.023 ± 0.006 0.42
Uterus 0.001 ± 0.000 0.018 ± 0.002 0.58
Total body 0.004 ± 0.000 0.029 ± 0.004 0.55
Effective dose (mSv/MBq) 0.010 ± 0.001 0.036 ± 0.009 0.61
\